To include your compound in the COVID-19 Resource Center, submit it here.

Basimglurant: Development discontinued

Roche discontinued development of RG7090 to treat Fragile X syndrome after the compound missed the primary and secondary endpoints in the double-blind, placebo-controlled, international Phase II Fragxis

Read the full 271 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE